Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

NCT06137755 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Vaccine-Preventable Diseases
Herpes Zoster

Interventions

BIOLOGICAL: CVI-VZV-001
BIOLOGICAL: Shingrix

Sponsor

CHA Vaccine Institute Co., Ltd.